1 Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37–49.
2 Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol. Urodyn. 2014; 33: 622–4.
3 Milsom I, Abrams P, Cardozo L, Roberts RG, Th€uroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87: 760–6.
4 Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003; 20: 327–36.
5 Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results oftheEPICstudy.Eur.Urol.2006;50: 1306–14.
6 Vaughan CP, Johnson TM, Ala-Lipasti MA et al. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur. Urol. 2011; 59: 629–36.
7 Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009; 103: 202–9.
8 Moons KGM, Altman DG, Reitsma JB et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann. Intern. Med. 2015; 162: W1–73.
9 National Institute of Diabetes and Digestive and Kidney Diseases. Prevention of bladder control problems (urinary incontinence) & bladder health. [Cited 20 Nov 2021.] Available from URL: https://www.niddk.nih.gov/ health-information/urologic-diseases/bladder-control-problems/prevention
10 Funada S, Tabara Y, Negoro H et al. Longitudinal analysis of bidirectional relationships between nocturia and depressive symptoms: the Nagahama study. J. Urol. 2020; 203: 984–90.
11 Funada S, Tabara Y, Setoh K et al. Impact of nocturia on mortality: the Nagahama study. J. Urol. 2020; 204: 996–1002.
12 Funada S, Luo Y, Yoshioka T et al. Protocol for development and validation of a prediction model for 5-year risk of incident overactive bladder in the general population: the Nagahama study. BMC Urol. 2021; 21: 78.
13 Homma Y,YoshidaM,SekiNet al. Symptom assessmenttool for overactive bladder syndrome–overactive bladder symptomscore.Urology2006;68: 318–23.
14 Tibshirani R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. B. Methodol. 1996; 58: 267–88.
15 Alba AC, Agoritsas T, Walsh M et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA 2017; 318: 1377– 84.
16 Van Calster B, McLernon DJ, van Smeden M et al. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019; 17: 230.
17 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 2006; 26: 565–74.
18 Steyerberg EW. Clinical Prediction Models. Springer, New York; 2009. [Cited 17 Oct 2021.] Available from URL: http://link.springer.com/10.1007/ 978-0-387-77244-8
19 Friedman J, Hastie T, Tibshirani R et al. glmnet: lasso and elastic-net regularized generalized linear models. 2021. [Cited 25 Oct 2021.] Available from URL: https://CRAN.R-project.org/package=glmnet
20 Chang W, Cheng J, Allaire JJ et al. shiny: web application framework for R. 2021. [Cited 25 Oct 2021.] Available from URL: https://CRAN.R-project.org/package= shiny
21 Hoogland J, van Barreveld M, Debray TPA et al. Handling missing predictor values when validating and applying a prediction model to new patients. Stat. Med. 2020; 39: 3591–607.
22 Collin SM, Metcalfe C, Donovan J et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UKpopulation-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008; 102: 1400–6.
23 Fukuta F, Masumori N, Mori M, Tsukamoto T. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study. BJU Int. 2012; 110: 1023–9.
24 Connolly TJ, Litman HJ, Tennstedt SL et al. The effect of mode of delivery, parity, and birth weight on risk of urinary incontinence. Int. Urogynecol. J. 2007; 18: 1033–42.
25 Zhang L, Zhu L, Xu T et al. A population-based survey of the prevalence, potential risk factors, and symptom-specific bother of lower urinary tract symptoms in adult chinese women. Eur. Urol. 2015; 68: 97– 112.
26 Gratzke C, Bachmann A, Descazeaud A et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur. Urol. 2015; 67: 1099–109.
27 Lee AJ, Garraway WM, Simpson RJ et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur. Urol. 1998; 34: 325–32.
28 Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC. Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J. Urol. 2011; 185: 571–7.
29 Riley RD, Hayden JA, Steyerberg EW et al. Prognosis research strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 2013; 10: e1001380.
論文の公開元へ
